*** The U.S. Food and Drug Administration (FDA) has approved Pfizer's (PFE) XALKORI capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is ALK-positive as detected by an FDA-approved test.

*******************************